{"celex_id": "32004R1876", "uri": "http://publications.europa.eu/resource/cellar/66529233-f35b-4332-a023-ff52ca5322e7", "type": "Regulation", "concepts": ["2300", "2666", "3156", "3178", "3577", "3813"], "title": "Commission Regulation (EC) No\u00a01876/2004 of 28 October 2004 amending Annex I of Regulation (EC) No\u00a0953/2003 to avoid trade diversion into the European Union of certain key medicines\n", "header": "29.10.2004 EN Official Journal of the European Union L 326/22\nCOMMISSION REGULATION (EC) No 1876/2004\nof 28 October 2004\namending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines\nTHE COMMISSION OF THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines\u00a0(1), and in particular Article 4(8) thereof,\nWhereas:\n(1) The Commission has received applications under Article 4 of Regulation (EC) No 953/2003 with respect to certain pharmaceutical products.\n(2) The Commission has determined that the applications received fulfil the requirements set out in Regulation (EC) No 953/2003 in accordance with the procedure laid down in Article 5(2) of that Regulation.\n(3) The applicants have been informed of the Commission decision to accept their applications.\n(4) It is therefore necessary to add the products concerned to Annex I to Regulation (EC) No 953/2003,", "main_body": ["The products and other details mentioned in the Annex to this Regulation shall be added to Annex I to Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines.", "This regulation enters into force on the day following its publication in the Official Journal of the European Union.\nIt shall be binding in its entirety and directly applicable in all Member States."], "attachments": "Done at Brussels, 28 October 2004.\nFor the Commission\nPascal LAMY\nMember of the Commission\n(1)\u00a0\u00a0OJ L 135, 3.6.2003, p. 5.\nANNEX\nProduct Manufacturer/exporter Country of destination Distinctive features Date of approval CN/TARIC code\u00a0(1)\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\nGlaxo Smith Kline,\nGSK House,\n980 Great West Road,\nBrentford, Middlesex,\nTW8 9GS,\nUnited Kingdom\n(1)\u00a0\u00a0Only if applicable.\u2019"}